Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in
combination with intra-cerebrospinal fluid (CSF) trastuzumab on overall survival rate at 12
months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal
evolution and requiring intrathecal therapy.